Susan Parker
Nurse Practitioner · Henagar, ALNPI 1376508218
Payments from drug & device makers
Across 330 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$883
- Novo Nordisk$746
- Amgen$682
- AbbVie$549
- GSK$366
- Lilly USA, LLC$277
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,398100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 55 | $883 |
| Novo Nordisk | 52 | $746 |
| Amgen | 43 | $682 |
| AbbVie | 34 | $549 |
| GSK | 24 | $366 |
| Lilly USA, LLC | 15 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Bayer | 10 | $185 |
| AstraZeneca | 9 | $129 |
| Scilex Pharmaceuticals Inc. | 7 | $129 |
| Mylan Specialty L.p. | 6 | $115 |
| Dexcom, Inc. | 5 | $88 |
| Abbott | 4 | $76 |
| Corcept Therapeutics | 3 | $71 |
| Pfizer | 4 | $69 |
| Merck | 4 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Boehringer Ingelheim | 4 | $66 |
| Sanofi-aventis U.S. LLC | 5 | $62 |
| Medtronic | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Exact Sciences | 3 | $44 |
| Indivior Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Sobi, Inc | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $30 |
| Lundbeck LLC | 1 | $23 |
| Almatica Pharma LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $9 |
How this compares
$5,398 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $147,727 |
| MounjaroTirzepatide | 94 | $118,319 |
| EliquisApixaban | 134 | $91,975 |
| JardianceEmpagliflozin | 87 | $72,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $58,598 |
| XareltoRivaroxaban | 61 | $46,864 |
| EntrestoSacubitril/Valsartan | 41 | $34,644 |
| ProliaDenosumab | 20 | $33,673 |
| FarxigaDapagliflozin Propanediol | 29 | $21,406 |
| LinzessLinaclotide | 27 | $19,117 |
| MyrbetriqMirabegron | 25 | $17,972 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,268 |
| TrulicityDulaglutide | 12 | $11,258 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,204 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $746 | $147,727125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $277 | $129,576106 claims |
| PfizerEliquis | $69 | $91,975134 claims |
| Boehringer IngelheimJardiance | $66 | $72,24787 claims |
| GSKTrelegy Ellipta, Shingrix, Incruse Ellipta | $366 | $70,814143 claims |
| NovartisEntresto | $883 | $34,64441 claims |
| AmgenProlia | $682 | $33,67320 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $129 | $32,60947 claims |
| AbbVieLinzess | $549 | $19,11727 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $62 | $12,26814 claims |
| MerckJanuvia | $69 | $9,37117 claims |
| BayerKerendia | $185 | $7,06511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Henagar
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Ashley HodgensMontgomery$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.